Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.68 |
| ▸ | HRH1 | P35367 | 8/20 | 0.68 |
| ▸ | DRD2 | P14416 | 3/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111799 | 0.87 | DRD3 (0.52) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL4768628 | 0.87 | DRD3 (0.69) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL4839391 | 0.84 | DRD3 (0.63) | DRD3KCNH2HRH1DRD2 | |
| SCHEMBL4836950 | 0.84 | DRD3 (0.53) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL4773705 | 0.81 | DRD3 (0.50) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL5104634 | 0.81 | DRD3 (0.81) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL2287102 | 0.81 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL4769841 | 0.81 | DRD3 (0.66) | DRD3KCNH2DRD2 | |
| SCHEMBL2316059 | 0.81 | DRD3 (1.00) | DRD3KCNH2HRH1 | |
| SCHEMBL2311126 | 0.81 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | claimed |
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1335915-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2008-01-02 | — | — | EP | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | DRD3 1/4885KCNH2 272/4885HRH1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.